The 20th Annual Mayo Clinic Hematology/Oncology Reviews is an extensive survey designed to provide updates and recent breakthroughs on the evaluation and treatment of cancer and blood disorders. The College of Medicine at the Mayo Clinic designed the program as an accredited postgraduate class, and it has been approved by the American Osteopathic Association for 17.50 hours of 2A accreditation. However, health care professionals should enquire as to whether their state board honors programs approved by the Florida Board.
The course will adopt an original approach by including case-based vignettes and didactic presentations within its framework. It will stress the practical aspects of cancer treatment in the hopes that these aspects will eventually lead to better clinical applications.
A topic that may well arise during course is mesothelioma. Malignant mesothelioma is a rare type of cancer affecting the lining of the chest and/or abdomen. Those with exposure to airborne asbestos particles are more likely to develop the mesothelioma disease. Treatment includes surgery, chemotherapy and radiation therapy or a combination of the three.
A notable contributor to the field of mesothelioma is Dr. David Sugarbaker. His specialty is thoracic oncology which is one of the most challenging fields in cancer research. He is considered one of the world's leading experts in the diagnosis and treatment of malignant pleural mesothelioma and a champion of further and more in depth study of the disease and its treatment.
Review registration starts at 7:00AM each morning, and lectures start one hour later. Topics discussed include Hematological Malignancies, Benign Hematology, Sarcomas and Melanomas, Lung Cancers, Head and Neck, Gynecologic Malignancies, Neuroendocrine Tumors, GU Malignancies, Breast Cancer and GI Cancers.
The review will address all of the following objectives:
- The most important and most clinically relevant new findings in hematology/oncology over the last year, as well as recent changes in the management of patients with AML and breast cancer.
-New recommendations coming from newly presented clinical research work that is applicable to their daily practice of hematology/oncology
- Promising new cancer drugs currently undergoing clinical trial evaluation that might be used in the treatment of gynecological malignancies.
- Data supporting new treatments for lung cancer.
- New treatments for head and neck cancer, melanoma, sarcomas, Neuroendocrine tumors and colon cancer.
- Therapeutic options for advanced and metastatic prostate cancer.
The registration fee is $575.00 for physicians and scientists and $475.00 for residents, PA’s, nurses and retirees. A registration form is available online on the Mayo Clinic Web site. You may cancel your registration 14 days or more before the course start date and receive a full refund (minus a $75 administrative fee). However, only written cancellation is accepted.
